期刊文献+

慢性丙型肝炎患者停药后复发的影响因素分析 预览 被引量:1

Causes and countermeasures for relapse after drug withdrawal in patients with chronic hepatitis C
在线阅读 下载PDF
收藏 分享 导出
摘要 目的探讨慢性丙型肝炎(CHC)患者停药复发的原因及影响因素。方法选取2010年4月-2013年3月于兰州市第一人民医院就诊及住院的患者101例,其中男36例,女65例,代偿期肝硬化患者26例,慢性肝炎患者75例,年龄19~71岁,所有患者均为初治患者。治疗前行血常规、生化、自身抗体、甲状腺功能、HCV RNA载量、HCV基因分型等检测。治疗第4、12、24周、治疗结束时、治疗结束后12、24、48、72、96周等时间点进行肝功能、血常规、HCV RNA载量的检测。停药后随访96周,根据是否检测出HCV RNA,分为复发组和未复发组,复发组中又分为24周内复发和获得持续性病毒学应答(SVR)复发两组,观察各组基线水平、4周病毒学应答率、生化学应答率,治疗方案等对复发的影响。计数资料组间比较采用χ2检验,不满足χ2检验条件时采用Fisher检验,计量资料组间比较采用t检验。结果 101例患者中71例患者获得快速病毒学应答(RVR),占70.3%;90例患者获得早期病毒学应答(EVR),占89.1%;9例患者无应答或治疗期间HCV RNA反弹,占8.9%。92例患者获得治疗末病毒学应答(ETVR),占91.1%,其中基因1b型患者28例,占获得ETVR例数的30.4%。非基因1型患者共64例,占获得ETVR例数的69.6%。获得ETVR的92例患者中接受标准化治疗方案60例,占65.2%,接受非标准化治疗方案患者32例,占34.8%。92例患者停药2年随访,30例患者停药复发,占ETVR的32.6%,其中13例停药24周内复发,占复发患者的43.3%。获得SVR后复发17例,占复发患者的56.7%,占SVR的21.5%,占ETVR的18.5%。复发组和未复发组在年龄、病毒载量、有无合并肝硬化、4周ALT复常率、RVR率及非标准化治疗率等方面差异有统计学意义(t值为2.624,χ2值分别为15.199、4.469、7.352、7.453、19.950,P值均〈0.05)。近期复发与获得SVR复发患者比较,在HCV RNA载量、是否采用标准化治疗两方面比较差异有统计学意义� Objective To study the causes and influential factors for relapse after drug withdrawal in patients with chronic hepatitis C (CHC). Methods One hundred and one cases of CHC, including 36 males and 65 females, who were outpatients or inpatients in our hospital, were enrolled as subjects. Twenty - six patients had compensated cirrhosis, and seventy - five had chronic hepatitis. Their age ranged from 19 to 71 years. All patients had no treatment history. Routine blood indices, biochemical parameters, autoautibodies, thyroid function, hepatitis C viral load (HCV RNA) , and hepatitis C virus (HCV) genotypes were evaluated before treatment. Liver function, routine blood indices, and HCV RNA load were evaluated at weeks 4, 12, 24, and the end of treatment, as well as 12, 24, 48, 72, and 96 weeks aiier treatment. The follow - up time after drug withdrawal was 96 weeks. All patients were divided into relapse group and sustained response group, according to whether HCV RNA was detected or not. Patients in the relapse group were further divided into two groups: relapse within 24 weeks and relapse after achieving sustained virological response (SVR). The effects of baseline levels, 4 - week virological response rates, biochemical response rates, and treatment regimen on relapse were assessed. Between - group comparison of categorical data was performed byx2 test, and between - group comparison of continuous data was performed by t test. Results In all patients, 71 patients ( 70. 3% ) had rapid virological response ( RVR), 90 patients ( 89.1% ) had early virological response, and 9 patients ( 8.9% ) had no response or restored HCV RNA during treatment. Among 92 patients (91.1%) with end - of - treatment virological response ( ETVR), 28 patients (30.4%) had genotype lb, while 64 patients (69.6%) had non -1 genotypes. Among 92 patients with ETVR, 60 patients ( 65.2% ) received the standard treatment, while 32 patients (34.8%) received the non - standard treatment. During
作者 张月荣 周宁 李象霖 吴丽阳 魏世芳 张耀弟 张月萍 ZHANG Yuerong, ZHOU Ning, LI Xianglin, et al. (Department of Injections Diseases, The First Peoples's Hospital of Lcmzhou, Lanzhou 730050, China)
出处 《临床肝胆病杂志》 CAS 2015年第9期1434-1438,共5页 Chinese Journal of Clinical Hepatology
关键词 肝炎 丙型 慢性 干扰素Α 利巴韦林 复发 危险因素 hepatitis C, chronic interferon - alpha ribavirin recurrence risk factors
作者简介 张月荣(1970-),女,主任医师,主要从事病毒性肝炎、肝硬化等各种肝脏疾病的诊治研究。 通信作者:李象霖,电子信箱:zhangliyr10@126.com。
  • 相关文献

参考文献18

  • 1陈志敏,陈铿,应若素,向芳菲,石裕明,李慧慧,刘惠媛.聚乙二醇化干扰素联合利巴韦林治疗慢性丙型肝炎的疗效及影响因素分析[J].中华实验和临床感染病杂志(电子版),2014,8(1):22-25. 被引量:16
  • 2HADZIYANNIS S J, SE-FIEH JR, MORGANTR, et al. Peginter- feron - alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomize d study of treatment duration and riba-virin in dose[J]. Ann Intern Med, 2004, 140(5):346 -355. 被引量:1
  • 3丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量:721
  • 4POORDAD F, MCCONEJ, BACON BR, etal. Boceprevirfor untreated chronic HCV genotypel infection [ J ]. N Engl J Med, 2011 , 364(26) : 1195 -1206. 被引量:1
  • 5慢性丙型肝炎抗病毒治疗专家共识[J].中华实验和临床感染病杂志(电子版),2009(3):59-64. 被引量:66
  • 6DESOMBERE I, van VLIERBERGHE H, COUVENT S, et al. Comparison of qualitative ( COBAS AMPLICOR HCV 2.0 ver- sus VERSANT HCV RNA) and quantitative ( COBAS AMPLI- COP, HCV monitor 2.0 versus VERSANT HCV RNA 3. O as- says for hepatitis C virus (HCV) RNA detection and quantifi- cation: impact on diagnosis and treatment of HCV infections [J]. J Clin Microbiol, 2005, 43(1): 2590-2597. 被引量:1
  • 7LEE SD, YU ML, CHENG PN, et al. Comparison of a 6- month course peg -interferon alpha -2b plus fibavirin and in- terferon alpha -2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan[ J ]. J Viral Hepat, 2005, 12(3): 283 -291. 被引量:1
  • 8MAZZARO C, ZORAT F, CAIZZI M, et aL Treatment with peg -interferon alpha -2b and ribavirin of hepatitis C virus - associated mixed cryoglobulinemia a pilot study[J]. J Hep- atol, 2005, 42(1 ): 632 -638. 被引量:1
  • 9KAINUMA M, FURUSYO N, KAJIWARA E, et al. Peg -interfer- on -2b plus ribavirin for older patients with chronic hepatitis C [J]. World J Gastreenterol, 2010, 16[38) : 4400 -4409. 被引量:1
  • 10YANG Z, ZHUANG L, YANG L, et al. Efficacy and tolerability of peginterferon e-2a and peginterferon o-2b, both plus ribavirin for chronic hepatitis C: a meta -analysis of random- ized controlled trials [ J ]. Gastroenterol Res Pract, 2013, 2013, 739029. 被引量:1

二级参考文献71

共引文献819

同被引文献6

引证文献1

二级引证文献2

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈